What's hot!

View all perspectives
What's Hot

New axSpA Criteria: Who gets left out?

Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.  

Watch video →

What Happens when CAR-T Fails Managing Disease Recurrence

Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.

Watch video →

‘Strong’ Treatment Predictions in Inflammatory Myositis

Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.

Watch video →

Imaging in Subclinical Psoriatic Arthritis

Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.

Watch video →

Are we failing in the treatment of RA-ILD?

Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.

Watch video →

PsA Potpourri: Probiotics & Head-to-Head Data

Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.

Watch video →

Combination Biologics in PsA: MRI Findings from AFFINITY

Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.  

Watch video →

How Many CAR-Ts Do We Need to Test Drive?

Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.

Watch video →

BMI Outranks Treatment in PsA Outcomes?

Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.

Watch video →

Dietary Interventions in PsA

Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.

Watch video →

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise

Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. 

Watch video →

Renal Biopsies in SLE

Dr. Andrea Fava reporting from EULAR 2026 in London.

Watch video →

RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk

Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London 

Watch video →

Day 4 Recap: EULAR 2026

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.

Watch video →

EULAR 2026 Recommendations: Immunization

Dr. Jiha Lee reporting from EULAR 2026 in London.

Watch video →

Making Methotrexate More Effective

Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London

Watch video →

Day 3 Recap: EULAR 2026

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288

Watch video →
CAR T on purple background

5 years since Patient ID001: Progress on CAR-T Therapy in RMD

Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?

Read more →
      #EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort:
      -enriched in Black patient

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months ago
      #EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort: -enriched in Black patients -poor response to B-cell depletion inc. Obi -non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab -High ferritin = flare @RheumNow https://t.co/3uDMigY8i2
      #EULAR2026 Signing off from the conference 🚆. A lot of learning points and things to consider for tomorrow’s practi

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months ago
      #EULAR2026 Signing off from the conference 🚆. A lot of learning points and things to consider for tomorrow’s practice, caught up with colleagues and formed new collaborations. Thank you @eular_org. Hope you enjoyed our @RheumNow coverage. See you in Berlin 🇩🇪 #EULAR2027 https://t.co/nyaBnHLrxr
      Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot

      Mrinalini Dey DrMiniDey

      2 months ago
      Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis. @ElenaNikiUK @RheumNow #EULAR2026 https://t.co/UmB63QBl7N
      Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks.

      SUA <300 μmol/L at W

      Antoni Chan MD (Prof) synovialjoints

      2 months ago
      Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks. SUA <300 μmol/L at Week 36: 63.8% vs 40.7% (p<0.0001) A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS
      Do probiotics improve disease activity in PsA?

      POS0290: no
      MEDISPA RCT n=66

      Multispecies probiotics not superior to pl

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      Do probiotics improve disease activity in PsA? POS0290: no MEDISPA RCT n=66 Multispecies probiotics not superior to placebo at week 12 #EULAR2026 @RheumNow https://t.co/1byJ1nB4GF
      #EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR0915

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months ago
      #EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1
      🏠 Take Home Messages from the early #axSpA session

      🔺 Earlier diagnosis is possible and better
      🔺 Early axSpA is

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      🏠 Take Home Messages from the early #axSpA session 🔺 Earlier diagnosis is possible and better 🔺 Early axSpA is not synonymous to mild 🔺 Longitudinally, early axSpA is heterogeneous 🔺 MRI has transformed the field ❗️Beware of pitfalls #EULAR2026 @RheumNow
      A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype

      Results from the Spanish REGISPON-3
      POS1352

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype Results from the Spanish REGISPON-3 POS1352 #EULAR2026 @RheumNow https://t.co/XicguAdXJ1
      How many patients with IBD have axSpA?

      POS1338 #EULAR2026 @RheumNow

      ⬇️⬇️⬇️ https://t.co/29qkrCnDYz

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      How many patients with IBD have axSpA? POS1338 #EULAR2026 @RheumNow ⬇️⬇️⬇️ https://t.co/29qkrCnDYz
      Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU?

      Yes! POS

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU? Yes! POS 1347 Multicenter randomised open-label trial N=56 #EULAR2026 @RheumNow https://t.co/kP7ropPkpC
      What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission?

      Data from 194 patients fro

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission? Data from 194 patients from the SELECT-AXIS2 RCT: ▶️ Remission maintained in 1/4 at48 weeks POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux
      #EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE ris

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months ago
      #EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk: -VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile) -No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD
      Making Methotrexate More Effective
      2 months ago
      https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t

      Janet Pope Janetbirdope

      2 months ago
      https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t
      LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic

      Antoni Chan MD (Prof) synovialjoints

      2 months ago
      LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK

      Podcasts

      • RheumNow EULAR 2026 Rheumatology Round Up
      • EULAR 2026 RA Topic Panel
      • CAR-T Topic Panel EULAR 2026

      Catch up on Conference Podcasts

      ×